Oncotelic Therapeutics (OTCQB: OTLC), a biopharmaceutical company developing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced that three abstracts featuring its investigational intravenous Deciparticle (TM) everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, to be held Dec. 9–12 in San Antonio, Texas. The abstracts collectively detail the clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial in HR⁺/HER2⁻ metastatic breast cancer.
Developed by Sapu Nano—a joint venture between Oncotelic and Dragon Oversea—Sapu003 is a novel IV formulation of everolimus designed to overcome the limitations of oral mTOR inhibitors such as Afinitor (R), including poor bioavailability and restricted tumor penetration. The acceptance of these abstracts at a major breast cancer conference underscores the potential significance of this approach. For more details, the full press release is available at https://ibn.fm/Ut6V8.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.
The acceptance of these abstracts is notable because it highlights the progress of Sapu003, which aims to improve the therapeutic index of everolimus by enabling intravenous delivery. Oral mTOR inhibitors like Afinitor are associated with significant side effects and limited efficacy due to poor absorption. By reformulating the drug as a nanoparticle, Oncotelic hopes to enhance tumor accumulation and reduce systemic toxicity. The ongoing Phase 1 trial will provide further insights into safety and preliminary efficacy.
For investors and followers of Oncotelic, updates are available in the company’s newsroom at https://ibn.fm/OTLC. The 2025 San Antonio Breast Cancer Symposium is a key venue for presenting data that could influence clinical practice and further development. The acceptance of these abstracts suggests that the scientific community recognizes the potential of this novel formulation.
